TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects aged 18-70 years~* Diagnosis of asthma consistent with Global Initiative for Asthma (GINA) steps 1 to 3~* Presumptive human rhinovirus infection~Exclusion Criteria:~* Current severe asthma exacerbation~* Severe asthma, GINA steps 4 or higher~* Uncontrolled or clinically significant medical condition, disease or event which could impact subject safety and/or study evaluations and/or compliance to the protocol~* Current smoker, ex-smoker of \<1 year, or history of smoking \>/=10 pack years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- BTA798 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adaptive COVID-19 Treatment Trial (ACTT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Admitted to a hospital with symptoms suggestive of COVID-19 infection.~2. Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures.~3. Subject (or legally authorized representative) understands and agrees to comply with planned study procedures.~4. Male or non-pregnant female adult \> / = 18 years of age at time of enrollment.~5. Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay in any specimen, as documented by either or the following:~   1. PCR positive in sample collected \< 72 hours prior to randomization; OR~      Exclusion Criteria:~  2. PCR positive in sample collected \>/= 72 hours prior to randomization, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking \>24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-2 infection.~6. Illness of any duration, and at least one of the following:~   1. Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR~  2. SpO2 \< / = 94% on room air, OR~  3. Requiring supplemental oxygen, OR~  4. Requiring mechanical ventilation.~7. Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 29.~8. Agrees to not participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 through Day 29.~Exclusion Criteria:~1. Alanine Transaminase (ALT) or Aspartate Transaminase (AST) \> 5 times the upper limit of normal.~2. Estimated glomerular filtration rate (eGFR) \< 30 ml/min (including patients receiving hemodialysis or hemofiltration).~3. Pregnancy or breast feeding.~4. Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours.~5. Allergy to any study medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 200 mg of Remdesivir placebo administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir placebo while hospitalized for up to a 10 days total course. n=286.
- Remdesivir (Type: EXPERIMENTAL): 200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10 days total course. n=286.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, age 22 years and older~* Subjects who are able and willing to give informed consent and able to attend all study visits~* Subjects with a diagnosis of Essential Tremor as confirmed from clinical history and examination by a neurologist or neurosurgeon specialized in movement disorder~* Subject exhibits a significant disability from their ET despite medical treatment~* Subjects should be on a stable dose of all ET medications for 30 days prior to study entry~* Subject is able to communicate sensations during the ExAblate Transcranial procedure~Exclusion Criteria:~* Subjects with unstable cardiac status~* Severe hypertension~* Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.~* Known intolerance or allergies to the MRI contrast agent including advanced kidney disease or severely impaired renal function~* Significant claustrophobia that cannot be managed with mild medication~* Current medical condition resulting in abnormal bleeding and/or coagulopathy~* Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage~* History of intracranial hemorrhage~* History of multiple strokes, or a stroke within past 6 months~* Subjects who are not able or willing to tolerate the required prolonged stationary supine position during treatment~* Are participating or have participated in another clinical trial in the last 30 days~* Subjects unable to communicate with the investigator and staff~* Subjects with a history of seizures within the past year~* Subjects with brain tumors

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transcranial ExAblate (Type: EXPERIMENTAL): Transcranial ExAblate
- Sham Transcranial ExAblate (Type: SHAM_COMPARATOR): Sham Treatment with Transcranial ExAblate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Infants may be eligible for this study if they:~* Were full term infants (at least 32 weeks gestation).~* Are 1 month of age or younger (preferably less than 2 weeks).~* Weighed at least 1,200 grams (2.5 lbs) at birth.~* Have confirmed cytomegalovirus.~* Have evidence of CMV infection of the CNS with or without evidence of other organ involvement.~Exclusion Criteria:~Infants will not be eligible for this study if they:~* Have concurrent bacterial infection.~* Have HIV infection.~* Have mild symptoms or no symptoms of CMV infection at birth.~* Have an abnormal brain development (hydranencephaly) or any devastating brain involvement.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Month
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 1 diabetes (according to American Diabetes Association \[ADA\] criteria) within the 8 weeks prior to study entry~* Weigh at least 25 kg (55 lbs)~* Insulin autoantibodies assessed within 10 days of any insulin use OR anti-glutamic acid decarboxylase (GAD) autoantibodies OR anti-ICA512/IA-2 autoantibodies~* Subjects or guardian(s) willing to provide informed consent~Exclusion Criteria:~* Prior participation in a clinical trial that could potentially affect diabetes condition or immunologic status~* Participation in another investigational clinical trial within the 6 weeks prior to study entry~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Anti-CD3 mAb Plus Diabetes Standard of Care Treatment (Type: EXPERIMENTAL): Subjects receive 1.) a 14-day course of anti-CD3 monoclonal antibody (mAb) intravenously (IV) comprised of daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 days of 826 µg/m2 \[Cycle 1\] and, when eligible per protocol, receipt of a second 14-day course after a 12-month interval (at month 13)\[Cycle 2\]. Note: Prior to May 2007, the course of IV daily doses of anti-CD3 mAb were: 57 µg/m2, 115 µg/m2, 230 µg/m2, 460 µg/m2, and 10 days of 919 µg/m2 and, when eligible per protocol, a second course after a 12-month interval (at month 13). 2.) and intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.~Iron supplementation initiated status post treatment randomization.
- Diabetes Standard of Care Treatment (Type: ACTIVE_COMPARATOR): Subjects receive intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.~Iron supplementation initiated status post treatment randomization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gardasil Vaccination in Post Stem Cell Transplant Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Female stem cell transplant recipient at least 90 days post stem cell transplant~OR~Female stem cell transplant recipient at least 90 days post HSCT and on immunosuppression~OR~The matched female stem cell transplant donor for an included stem cell transplant recipient~OR~Healthy female subject~Age greater than or equal to 18 years and less than or equal to 50 years~EXCLUSION CRITERIA:~Vaccine Recipient:~Obvious HPV condyloma or obvious severe dysplasia (greater than or equal to CIN II) warranting treatment~History of severe adverse reaction to any components (yeast, eggs, monosodium glutamate or neomycin) of the quadrivalent HPV vaccine.~Untreated or persistent life-threatening infections not controlled by current treatment~Uncontrolled chronic GVHD i.e. highly active eGVHD requiring immediate intervention~Pregnant or breast feeding or unwilling to be abstinent or practice effective contraception during the study period (note: patients who have been rendered infertile with total body irradiation are eligible)~Enrollment in another vaccine clinical trial during the study period~Enrollment of healthy volunteer in a drug clinical trial during the study period~Inability to comprehend the investigational nature of the study and provide informed consent\<TAB\>~Prior Gardasil or other HPV vaccination~Persistent or recurrent malignancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: ACTIVE_COMPARATOR): Female subjects post stem cell transplant on no systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
- Cohort 2 (Type: ACTIVE_COMPARATOR): Female subjects post stem cell transplant with chronic GVHD requiring systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
- Cohort 3 (Type: ACTIVE_COMPARATOR): Healthy normal female volunteers. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically documented gastric or gastroesophageal junctional adenocarcinoma (not amenable to curative therapy)~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1~* Adequate hematological, liver and kidney function. Measurable or non-measurable, but evaluable disease using RECIST v1.1~* Fibroblast growth factor receptor 2b (FGFR2b) overexpression as determined by a centrally performed immunohistochemistry tissue test and/or FGFR2 gene amplification as determined by a centrally performed circulating tumor deoxyribonucleic acid (ctDNA) blood based assay~* Candidate for mFOLFOX6 chemotherapy~Key Exclusion Criteria:~* Untreated or symptomatic central nervous system (CNS) metastases~* Clinically significant cardiac disease,~* Peripheral sensory neuropathy \>/= Common Terminology Criteria for Adverse Events (CTCAE) Grade 2~* Active infection requiring systemic treatment~* Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known active or chronic hepatitis B or C infection~* Prior treatment with any selective inhibitor of the fibroblast growth factor (FGF)-FGFR pathway~* Known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer~* Known positivity for human epidermal growth factor receptor 2 (HER2)~* Women who are pregnant or breastfeeding~Note: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bemarituzumab + mFOLFOX6 (Type: EXPERIMENTAL): Participants received 15 mg/kg bemarituzumab administered every 2 weeks (Q2W) with a single additional bemarituzumab 7.5 mg/kg dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
- Placebo + mFOLFOX6 (Type: PLACEBO_COMPARATOR): Participants received placebo for bemarituzumab administered every 2 weeks with a single additional placebo dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of type 2 diabetes mellitus prior to informed consent and an estimated glomerular filtration rate of \<90 ml/min.~2. Male and female patients on diet and exercise regimen who are pre-treated with any antidiabetic therapy and are on the maximum tolerated dose which has been unchanged for 12 weeks prior to randomisation.~3. HbA1c greater than or equal to 7.0% and less than or equal to 10.0% .~4. Aged 18 years or above.~5. Body Mass Index less than or equal to 45 kg/m2~Exclusion criteria:~1. Uncontrolled hyperglycaemia defined as \>13.3 mmol/L after an overnight fast during placebo run-in.~2. Impaired renal function, defined as an estimated glomerular filtration rate \<15 ml/min.~3. Renal impairment requiring any form of chronic dialysis.~4. Requiring acute dialysis within three months prior to informed consent.~5. Renal transplant recipient.~6. Myocardial infarction, stroke or Transient Ischemic Attack within three months prior to informed consent.~7. Indication of liver disease.~8. Bariatric surgery within the past two years.~9. Medical history of cancer.~10. Blood dyscrasias or any disorders causing hemolysis or unstable red blood cell.~11. Contraindications to pre-existing background antidiabetic therapy.~12. Treatment with anti-obesity drugs.~13. Current treatment with systemic steroids or change in dosage of thyroid hormones within six weeks prior to informed consent or any other uncontrolled endocrine disorder except Type 2 Diabetes.~14. Pre-menopausal women who are nursing or pregnant or are of child-bearing potential and are not practising an acceptable method of birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 low dose (Type: EXPERIMENTAL): BI 10773 tablets once daily
- BI 10773 high dose (Type: EXPERIMENTAL): BI 10773 tablets once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching BI 10773

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Location Initiated Individualized Texts for Adolescent Health (LIITAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* eat restaurant food at least 3 times a week and have a parent who agrees to participate.~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Full version of the LIITah App. (Type: EXPERIMENTAL): Participants will be given the LIITAH app. which consists of 1) enhanced location identification (ELI), 2) self reported nutrients by annotated photos (SNAP), 3) delivery of individually and culturally tailored point of purchase (POP) prompts along with tailored messages sent at other times of the day, 4) use of app. in connection with parents, 5) goal setting, 6) a point system
- Partial App. (ELI and SNAP only) (Type: ACTIVE_COMPARATOR): Participants will be given only the ELI and SNAP components. It will detect their presence in a restaurant and allow users to document their purchases by submitting annotated photos, but it will not deliver any POP prompts encouraging them to make healthy choices, or messages at other times of the day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/= 18 years of age~* Active moderate to severe rheumatoid arthritis of \>/= 6 months duration~* \>/=1 non-biologic DMARD and/or anti-TNF therapy at stable dose for \>/=8 weeks at any time prior to study treatment~* Inadequate clinical response to non-biologic DMARD or anti-TNF therapy~* Oral corticosteroids must be at stable dose for at least 25 out of 28 days prior to first dose of study drug~Exclusion Criteria:~* Pregnant or lactating women~* Major surgery (including joint surgery) within 8 weeks prior to screening or major surgery planned within 6 months of enrolment~* Rheumatic autoimmune disease other than RA~* Functional class IV (ACR classification)~* Prior history of or current joint disease other than RA~* Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline~* Previous treatment with RoActemra/Actemra~* Known active current or history of recurrent infection~* History of or currently active primary or secondary immunodeficiency~* Active tuberculosis requiring treatment within the previous 3 years~* Positive for HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metyrapone as Additive Treatment in Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of major depressive disorder; single or recurrent according to DSM-IV criteria (296.2 or 296.3)~* A minimum baseline Hamilton score of 18 points on the Hamilton Rating Scale for Depression (HamD; 21-item version)~* Age from 18 to 75 years~* A drug free period of at least 5 days from antidepressants, antipsychotics, mood stabilizers and all other medications except for mild antihypertensive agents~* A negative urinary drug screening diagnosis~Exclusion Criteria:~* A current DSM-IV diagnosis for other axis I psychiatric disorders~* Serious medical conditions, especially those associated with adrenal insufficiency~* Pregnancy, nursing or refusal to use a reliable method of birth control in women.~Participants were randomly assigned to a study group if they met these criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete